Thursday, May 19, 2022 8:00:28 PM
I see reason to get excited about the citrus potential.
Good to hear that they already made an application with EPA.
Will require testing .... OK.
After 1st test ... looks promising, so going forward with further test.
After 2nd test ... went well, so now will do some more testing.
After 3rd test .... hmmm, lets schedule some more testing.
testing on different fruits, then at different locations, different soils, different temperatures ...
So ... lets do some more testing.
The above is kind of how it feels as a shareholder hearing about the Oil & Gas testing efforts.
At some point I think PCT needs to put into some context how much further testing they might envision, and the cost and estimated time for such.
And ... they should provide some context to what degree this might boost revenues and NOI.
Will they eventually see an Oil & Gas potential of $2Million/year, with Cost of Goods $1.5 Million, before overhead costs?
Or do they believe it could add $5M or $10M to NOI within a year or two?
I know, I know ... Art does not like to make forecasts until the ink has dried.
But ... some guidance would be helpful.
Same as above in regards to citrus testing, and revenue/NOI potential.
Case in point: I cringe when I see PCT boasting on social media that they have been busy putting together an outgoing order for fluids and/or equipment, with pictures, and then seeing the disappointing quarterly revenues and large Net Operating Losses.
They need to figure out a way to get out of the hole (ie Losses).
I realize the Debt Burden was awful and has seen improvement, but they still need to start bringing in more bucks than having bucks leaving the company.
Recent PCTL News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 02:05:09 PM
- Form 15-12G/A - Securities registration termination [Section 12(g)]: [Amend] • Edgar (US Regulatory) • 07/18/2023 07:06:52 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/13/2023 04:32:57 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM